450 related articles for article (PubMed ID: 27830568)
1. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Samudra N; Patel N; Womack KB; Khemani P; Chitnis S
Drugs Aging; 2016 Dec; 33(12):855-863. PubMed ID: 27830568
[TBL] [Abstract][Full Text] [Related]
2. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
3. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
4. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions for psychosis in Parkinson's disease patients.
Friedman JH
Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
[TBL] [Abstract][Full Text] [Related]
6. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
[No Abstract] [Full Text] [Related]
7. Current Understanding of Psychosis in Parkinson's Disease.
Ojo OO; Fernandez HH
Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
[TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Hubbard D; Hacksell U; McFarland K
Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
[TBL] [Abstract][Full Text] [Related]
9. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
McFarland K; Price DL; Bonhaus DW
Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
[TBL] [Abstract][Full Text] [Related]
10. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
12. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
[TBL] [Abstract][Full Text] [Related]
13. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
[TBL] [Abstract][Full Text] [Related]
14. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
Duits JH; Ongering MS; Martens HJM; Schulte PFJ
Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
[TBL] [Abstract][Full Text] [Related]
15. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
[TBL] [Abstract][Full Text] [Related]
16. Pimavanserin for the treatment of Parkinson's disease psychosis.
Chendo I; Ferreira JJ
Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
Kyle K; Bronstein JM
Parkinsonism Relat Disord; 2020 Jun; 75():55-62. PubMed ID: 32480308
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin for the treatment of Parkinson's disease psychosis.
Friedman JH
Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
[TBL] [Abstract][Full Text] [Related]
19. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
20. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
Moreno GM; Gandhi R; Lessig SL; Wright B; Litvan I; Nahab FB
Neurology; 2018 Oct; 91(17):797-799. PubMed ID: 30258020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
